Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
The Sweet Truth: Unwrapping the Science of Semaglutide
Semaglutide, also known as Ozempic and Wegovy, has become increasingly popular -- but why? Here we discuss the mechanism behind these drugs, how they've become so well known, and what current research says about their long-term effects.
Evaluation of TruVivo, an All-Human Hepatocyte Model for Mechanistic DMPK Investigations
Join Diane Ramsden, PhD, and Lindsey Whaley, MS, for an inside look at TruVivo™, a novel all-human in vitro hepatocyte system developed by LifeNet Health LifeSciences.
#ExpertAnswers: Frauke Greve and Anna Borgström on Hepatic Safety Using 3D Liver Spheroids
Frauke Greve and Anna Borgström from InSphero highlight the latest advancements in hepatic safety assessment using 3D liver spheroids.
What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence
Join three panelists who provide a practical overview of how and why to use data from Medicare for real world studies.
Medicare Part D: Price Negotiation Panel Discussion
Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
The 3D DILI Model of Success – from Biological Relevance to Industry Application
Dr. Anna Borgström and Dr. Frauke Greve present the latest advancements in hepatic safety assessment using 3D liver spheroids.
#ExpertAnswers: Audrey Dubourg and Gareth Guenigault on the Organ-On-A-Chip Approach
Audrey Dubourg and Gareth Guenigault from CN Bio discuss the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Novel Targets for Alzheimer’s Disease Treatment: Medin and PLD3
Given that Alzheimer's disease is multifactorial and heterogenous, drug development progress is more likely to occur if multiple pathways are considered. Two recent Nature publications have potentially identified medin and PLD3 as new targets for Alzheimer’s disease treatment, which we summarize in this mini-review.
APS Physiology in Disease Modeling and Drug Development Roundtable
Key opinion leaders in cardiovascular physiology and bioengineering discuss best practices and challenges when modeling cardiomyopathies and other cardiovascular diseases using stem cells, engineered tissues and other novel platforms.
#ExpertAnswers: Andrew Taylor on Drug Metabolism
Andrew Taylor provides an overview of processes by which drugs are metabolized and talks about the importance of drug metabolism and drug-drug interaction studies.
It’s Life, but Not As We Know It: How Predictive Human Organ Models Are Transforming and Reshaping the Efficiency of Drug Discovery
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Are In Vitro Metabolism and Drug-Drug Interaction Studies Critical for an Investigational New Drug Application?
Andrew G. Taylor, PhD provides an overview of processes by which drugs are metabolized and discusses the importance of drug metabolism and drug-drug interaction studies.
Overcoming Critical Issues in Glioblastoma Multiforme (GBM) Therapeutic Development
This article, originally published on Scientist.com, reviews the current standard of care for glioblastoma multiforme (GBM), challenges in developing accurate preclinical GBM models and effective therapies, and the future of GBM drug discovery.
An Introduction to Infectious Disease Modeling
Hear ICON experts give an in-depth overview of infectious disease modeling with a focus on assessment of interventions and its challenges.
Syapse Real-World Dialogue: Advancing Patient Care through Real-World Data, Machine Learning, and Systems Biology
Join Drs. Nitin Baliga and Thomas Brown for an in-depth discussion on utilizing real-world data, machine learning, and systems biology for benefiting therapeutic development.
Combination Therapy for Cancer Treatment
The combination of anti-cancer drugs, or combination therapy, has been hailed as a “cornerstone of cancer therapy” since it targets key pathways synergistically, thereby enhancing efficacy compared to monotherapies. This blog takes a look at a recent publication in Nature, which reported the effects of 2025 pairwise drug combinations in breast, colon, and pancreatic cell lines.
#ExpertAnswers: Bin Xie on Drug Development for Immuno-Oncology
Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
#ExpertAnswers: Anuj Kalsy and Robert Snyder On The Variant-Rich Biobank
Anuj Kalsy and Robert Snyder showcase Precision for Medicine's variant-rich biobank, including discussion on biospecimen types, applications, screening methods, and support for companion diagnostic development.
The Variant-Rich Biobank: An Insider’s Look
Experts provide a showcase of Precision for Medicine's variant-rich biobank. including discussion on biospecimen types, applications, screening methods, and support for companion diagnostic development.
Current and Novel Immuno-Oncology Drug Evaluation Methods via Humanized Mouse Models
Dr. Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
Cutting Edge Conversations: Challenges in Sourcing Human Biosamples
Richard Kondo, McLean Collins, and Cathie G. Miller highlighted Episode 3 of the Cutting Edge Conversations series focused on innovations in the area of sourcing human biosamples for research. The event focused on sourcing human samples for research, including the value and necessity of working with human tissue during drug discovery, as well as some of the distinct challenges researchers face.
Bruker Micro-CT/XRM User Meeting
A two-day virtual user meeting showcasing state-of-the-art applications in both life and material sciences, and provides the latest Bruker news about hardware and software.
Detection of Protein Aggregation During Biopharmaceutical Development: The Role of Orthogonal Techniques
Dr. Danny Chou discusses the opportunities and challenges in orthogonal particle analysis, and how flow imaging microscopy and light obscuration can be used for formulation development and quality control.
#ExpertAnswers: Alexandra Lubin & Jason Otterstrom on Automated Microscopy
Experts discuss the use of deep learning-powered automated microscopy and image analysis for fast, in vivo zebrafish screening.
